Cumberland Pharmaceuticals
CPIX
34 hedge funds and large institutions have $38.3M invested in Cumberland Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more capital invested
Capital invested by funds: $38.2M → $38.3M (+$76K)
0.39% less ownership
Funds ownership: 34.39% → 34% (-0.39%)
6% less funds holding
Funds holding: 36 → 34 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.44M |
| 2 |
Renaissance Technologies
New York
|
+$136K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$62K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$57.8K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$33.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$2.75M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$164K |
| 3 |
BlackRock
New York
|
-$120K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$73K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $70K | – | – | – |
|
27
Russell Investments Group
London,
United Kingdom
| $37K | – | – | – |
|
|
NFA
28
Nationwide Fund Advisors
Columbus,
Ohio
| $27K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $22K | +$11.4K | +1,728 | +123% |
|
|
OC
30
Oakworth Capital
Birmingham,
Alabama
| $21K | – | – | – |
|
31
SEI Investments
Oaks,
Pennsylvania
| $8K | +$3.98K | +603 | +103% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $7K | +$6.74K | +1,022 | New |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $5K | +$449 | +68 | +10% |
|
|
MA
34
MUFG Americas
New York
| $2K | – | – | – |
|
|
35
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$73K | -10,550 | Closed |
|
36
Walleye Trading
New York
| – | -$3 | -438 | Closed |
|
|
TDC
37
Thompson Davis & Co
Richmond,
Virginia
| – | -$1K | -200 | Closed |
|
CPIX Hedge Fund Activity: Q2 2017 in Review
34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2017, worth a combined $38.3M — up 0.2% from $38.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CPIX and 1 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.44M. The largest seller was Ariel Investments, cutting an estimated $2.75M.
- 34 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2017, down from 36 in Q1 2017.
- Funds reported $38.3M of Cumberland Pharmaceuticals stock for Q2 2017, up 0.2% quarter-over-quarter.
- 1 fund opened new Cumberland Pharmaceuticals positions in Q2 2017 and 3 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q2 2017 was Stonepine Capital Management, an estimated $2.44M added.
- The largest Cumberland Pharmaceuticals seller in Q2 2017 was Ariel Investments, an estimated $2.75M sold.
Based on aggregated 13F filings for Q2 2017.